Bassett William W, Cooperberg Matthew R, Sadetsky Natalia, Silva Stefanie, DuChane Janeen, Pasta David J, Chan June M, Anast Jason W, Carroll Peter R, Kane Christopher J
Department of Urology, Urologic Outcomes Research Group, University of California, School of Medicine, Comprehensive Cancer Center, San Francisco, California, USA.
Urology. 2005 Nov;66(5):1060-5. doi: 10.1016/j.urology.2005.05.040.
To determine the association between obesity and prostate cancer recurrence after primary treatment with radical prostatectomy.
Data were abstracted from CaPSURE, a disease registry of 10,018 men with prostate cancer. We included 2131 men who had undergone radical prostatectomy between 1989 and 2003 and had body mass index (BMI) information available. Recurrence was defined as two consecutive prostate-specific antigen (PSA) levels of 0.2 ng/mL or greater or any second treatment. Patients were risk stratified using the PSA level, Gleason grade, and clinical T stage.
Patients were followed up for a median of 23 months. Of the 2131 patients, 251 (12%) developed recurrence at a median of 13 months (range 1 to 107); 183 (9%) of these men had PSA failure and 68 (3%) received a second treatment. After adjusting for risk group, ethnicity, age, and comorbidities, a significant association was found between an increasing BMI and disease recurrence (P = 0.028). Very obese patients (BMI 35 kg/m2 or more) were 1.69 times more likely to have recurrence relative to men of normal weight (BMI less than 25.0 kg/m2; 95% confidence interval [CI] 1.01 to 2.84). An increasing PSA level (P <0.0001) and Gleason grade (P <0.0001) were also associated with recurrence. Ethnicity was not significantly associated with either BMI or PSA recurrence (P = 0.685 and P = 0.068, respectively).
The results of our study have shown that obesity is an independent predictor of prostate cancer recurrence. Because of the increased comorbidities and greater rates of recurrence, obese individuals undergoing radical prostatectomy need vigilant follow-up care.
确定肥胖与根治性前列腺切除术后前列腺癌复发之间的关联。
数据取自CaPSURE,这是一个有10018名前列腺癌男性患者的疾病登记库。我们纳入了1989年至2003年间接受根治性前列腺切除术且有体重指数(BMI)信息的2131名男性。复发定义为连续两次前列腺特异性抗原(PSA)水平达到0.2 ng/mL或更高,或接受任何二次治疗。使用PSA水平、Gleason分级和临床T分期对患者进行风险分层。
患者的中位随访时间为23个月。在2131名患者中,251名(12%)在中位时间13个月(范围1至107个月)出现复发;其中183名(9%)男性出现PSA失败,68名(3%)接受了二次治疗。在对风险组、种族、年龄和合并症进行调整后,发现BMI升高与疾病复发之间存在显著关联(P = 0.028)。极度肥胖患者(BMI 35 kg/m2或更高)相对于正常体重男性(BMI低于25.0 kg/m2)复发的可能性高1.69倍(95%置信区间[CI] 1.01至2.84)。PSA水平升高(P <0.0001)和Gleason分级升高(P <0.0001)也与复发有关。种族与BMI或PSA复发均无显著关联(分别为P = 0.685和P = 0.068)。
我们的研究结果表明,肥胖是前列腺癌复发的独立预测因素。由于合并症增加和复发率更高,接受根治性前列腺切除术的肥胖个体需要密切的随访护理。